NEW: Vivek Ramaswamy’s Company Spent Over $70,000 Lobbying the Federal Government for Development & Approval of COVID-19 Drugs
June 11, 2026
Columbus, Ohio- New reporting from Politico’s Influence newsletter revealed that Vivek Ramaswamy’s company spent more than $70,000 lobbying the federal government for the development and approval of COVID-19 drugs. Federal lobbying records show Ramaswamy’s company spent approximately $50,000 lobbying the National Institutes of Health and the Executive Office of the President as well as approximately $20,000 lobbying Congress.
This new reporting from Politico follows bombshell reporting from the Associated Press that revealed Ramaswamy pushed for a national COVID-19 registry to segregate Americans based on immunity status. Ramaswamy’s company profited over $2.2 billion from the COVID-19 vaccine. He served on Ohio’s COVID-19 response team, then paid a Wikipedia editor to scrub his involvement.
“Scam artist Vivek Ramaswamy has given Ohioans yet another reason to not believe a word he says,” said Ohio Democratic Party spokeswoman Katie Seewer. “His extreme proposal to ‘segregate’ Americans based on immunity status, his billions in profit from the COVID-19 vaccine, and now his massive investment in lobbying the federal government are all more proof that the only person Vivek Ramaswamy is looking out for is Vivek Ramaswamy.”
READ: FIRST IN PI — RAMASWAMY’S COVID LOBBYING:
- A biotech company founded by Vivek Ramaswamy spent more than $70,000 in 2020 and 2021 to lobby the federal government for the development and approval of COVID-19 drugs, Jacob reports.
- Acton’s campaign says Ramaswamy’s rhetoric contradicts his actions as a biotech executive at the time. Democrats have also criticized another one of Ramaswamy’s companies that pushed for a national COVID registry that would have segregated Americans based on COVID-19 vaccine status during the pandemic. Ramaswamy also reportedly paid to have his role on the state’s COVID response team scrubbed from his Wikipedia page.
- Ramaswamy’s campaign and Roivant didn’t respond to requests for comment.
###